home / stock / cytr / cytr news

CYTR News and Press, CytRx Corporation From 05/13/21

Stock Information
Company Name: CytRx Corporation
Stock Symbol: CYTR
Market: NASDAQ
Website: cytrx.com
Menu
CYTR CYTR Quote CYTR Short CYTR News CYTR Articles CYTR Message Board
Get CYTR Alerts

News, Short Squeeze, Breakout and More Instantly...
CYTR - CytRx Comments on Quarterly Results and Year-to-Date Progress

Continues Focusing on Near-Term Revenue Opportunities Linked to Orphazyme’s Potential Regulatory Approvals for Arimoclomol in the Treatment of Niemann-Pick Disease Type C CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a spec...
CYTR - CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that the ORARIALS-01 pivotal trial for ...

CYTR - CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis

CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that its phase 2/3 trial evaluating ari...

CYTR - CytRx reports FY results

CytRx (CYTR): FY GAAP EPS of -$0.19.Cash and cash equivalents of $10M10KPress Release For further details see: CytRx reports FY results

CYTR - CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the fourth quarter and fiscal...

CYTR - CytRx (CYTR) Investor Presentation - Slideshow

The following slide deck was published by CytRx Corporation in conjunction with this event. For further details see: CytRx (CYTR) Investor Presentation - Slideshow

CYTR - CytRx Highlights Orphazyme's Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme Announces the Global Brand Name for Arimoclomol – MIPLYFFA – Ahead of Prospective FDA and EMA Approvals Expanded its Early Access Program for NPC in the U.S. and Europe as Well as Expectation of European Regulatory Decision by Q4 2021 ...
CYTR - CytRx Highlights Orphazyme's Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Christophe Bourdon’s Deep Commercialization Background and Vast International Experience Make Him the Ideal CEO For Orphazyme CEO Relocation to Copenhagen Seen as a Positive Sign of the Commercial Potential of Arimoclomol CytRx Corporation (OTCQB: CYTR...

CYTR - CytRx to Participate in Upcoming Investor Conferences

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Exe...

CYTR - CytRx is Added to the LD Micro Index

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it is now a part of the LD Micro Index ...
Previous 10 Next 10